BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yao M, Pan LH, Yao DF. Glypican-3 as a specific biomarker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:122-123. [PMID: 25865682 DOI: 10.1016/s1499-3872(15)60350-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 El-Saadany S, El-Demerdash T, Helmy A, Mayah WW, El-Sayed Hussein B, Hassanien M, Elmashad N, Fouad MA, Basha EA. Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas. Asian Pac J Cancer Prev 2018;19:811-7. [PMID: 29582639 DOI: 10.22034/APJCP.2018.19.3.811] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
3 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease 2019;30:193-200. [PMID: 31179356 DOI: 10.1007/s13337-019-00517-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology 2017;6:e1137418. [PMID: 28197361 DOI: 10.1080/2162402X.2015.1137418] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
5 Chen J, Zhao J, Ma R, Lin H, Liang X, Cai X. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e103952. [PMID: 25093414 DOI: 10.1371/journal.pone.0103952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
6 Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Sci Rep 2017;7:9608. [PMID: 28852111 DOI: 10.1038/s41598-017-10083-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
7 Khattab M, Fouad M, Ahmed E. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2474-2481 [PMID: 26483869 DOI: 10.4254/wjh.v7.i23.2474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Li J, Wang T, Jin B, Li W, Wang Z, Zhang H, Song Y, Li N. Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: A systematic review with meta-analysis. Int J Biol Markers. 2018;1724600818784409. [PMID: 30071741 DOI: 10.1177/1724600818784409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Tong Y, Tong K, Zhu Q, Wu Y, Yang Y, Zhang J, Hu P, Yan S. Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via the HIF-1α/c-Myc Axis in HepG2 Cells. Onco Targets Ther 2019;12:10663-70. [PMID: 31824173 DOI: 10.2147/OTT.S227215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang SY, Cao N, Chen MK, Zhang LD, Bai YQ, Ding SZ, Yang YX. FAT 10 protein as a potential serological marker in the diagnosis of hepatocellullar carcinoma. Clin Res Hepatol Gastroenterol 2017;41:711-4. [PMID: 28754570 DOI: 10.1016/j.clinre.2017.06.003] [Reference Citation Analysis]
12 Jeon Y, Jang ES, Choi YS, Kim JW, Jeong SH. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol. 2016;22:359-365. [PMID: 27729630 DOI: 10.3350/cmh.2016.0033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
13 Cui X, Li Z, Gao PJ, Gao J, Zhu JY. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:157-63. [PMID: 25865688 DOI: 10.1016/s1499-3872(15)60349-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Hodeib H, ELshora O, Selim A, Sabry NM, El-Ashry HM. Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electron Physician 2017;9:3492-8. [PMID: 28243398 DOI: 10.19082/3492] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741-767. [PMID: 28621802 DOI: 10.1002/med.21455] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
16 Chen JJ, Xie CM, Wang CR, Wan Y, Dong ZN, Li M, Xu WW. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. J Fluoresc. 2017;27:1479-1485. [PMID: 28429175 DOI: 10.1007/s10895-017-2087-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xu D, Su C, Sun L, Gao Y, Li Y. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Ann Hepatol. 2019;18:58-67. [PMID: 31113610 DOI: 10.5604/01.3001.0012.7863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
19 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhang Y, Gao J, Bao Y, Liu Y, Tong Y, Jin S, Zhao Q. Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. Biomarkers 2021;:1-9. [PMID: 34787036 DOI: 10.1080/1354750X.2021.2008009] [Reference Citation Analysis]
21 Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:8925-35. [PMID: 30573979 DOI: 10.2147/OTT.S186230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
22 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
23 Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, Ohno A, Kondo K, Kataoka H. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137:1643-1651. [PMID: 25784484 DOI: 10.1002/ijc.29518] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
24 Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers. 2014;2014:127831. [PMID: 25378766 DOI: 10.1155/2014/127831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
25 Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 275-283 [PMID: 26755876 DOI: 10.3748/wjg.v22.i1.275] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
26 Pan C, Wang X, Chen W, Tao C, Xu X, Jin L, Chen Y, Zhu L, Zhou L, Pan Z. Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software. Med Oncol. 2015;32:359. [PMID: 25432695 DOI: 10.1007/s12032-014-0359-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
27 Han N, Wang W, Lu D, Wang H, Ma X, Fan X, Li F. A novel, rapid, and sensitive homogeneous sandwich detection method of Glypican-3 as a serum marker for hepatocellular carcinoma. Chem Commun 2017;53:12209-12. [DOI: 10.1039/c7cc06305a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Chen J, Yu Y, Ji T, Ma R, Chen M, Li G, Li F, Ding Q, Kang Q, Huang D, Liang X, Lin H, Cai X. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma. Cancer Med 2016;5:2678-87. [PMID: 27650414 DOI: 10.1002/cam4.788] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
29 Zhang SY, Lin BD, Li BR. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. FEBS Open Bio 2015;5:240-4. [PMID: 25870783 DOI: 10.1016/j.fob.2015.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]